LGVN Longeveron Inc. (NASDAQ) pre-market 17 Mar 2026: Q4 earnings catalyst

The LGVN stock is trading pre-market on 17 Mar 2026 as Longeveron Inc. prepares to release Q4 2025 results after market hours. Investors are watching price $0.89, volume 25,293,342, and the earnings release scheduled for 16:00 EDT. The company’s EPS is -0.98 and the trailing PE reads -0.91, so clinical readouts and cash guidance will drive the move. This earnings spotlight focuses on what numbers could change the stock’s short-term path and which catalysts traders should track in the NASDAQ United States session.

Earnings preview: LGVN stock Q4 details and timing

Longeveron Inc. (LGVN) will announce Q4 2025 results on 17 Mar 2026 at 16:00 EDT. The market currently prices the stock at $0.89 with a market cap of $18,937,198.00 and 21,332,881 shares outstanding. Analysts will focus on revenue trends, cash runway commentary and any clinical updates for LOMECEL-B. The company’s trailing EPS is -0.98 and revenue per share TTM is 0.08, so management commentary on R&D pacing and financing matters most.

What to watch in the LGVN stock earnings report

Primary items: updated cash balance, guidance for 2026, enrollment or endpoint updates for key trials, and any collaboration news. Cash per share stands at $0.50 and current ratio is 2.09, which frames runway talk. Expect questions on operating cash flow per share of -0.91 and free cash flow per share of -0.92. Clear answers here could reduce the stock’s post-release volatility.

MarketBeat flagged the Q4 release and a separate price-target note; see the earnings notice and price-target commentary for background MarketBeat earnings report and MarketBeat forecast.

Market reaction and technicals for LGVN stock

Pre-market action shows the stock off -8.81% from the previous close of $0.97 with a session high of $1.22 and low of $0.88 as traders reposition ahead of results. Volume is elevated at 25,293,342 versus an average of 5,022,274, a 5.00x relative volume reading. Technical indicators show RSI near 69.29 and ADX 33.83, pointing to a strong short-term trend and possible overbought conditions.

High relative volume plus a tight 50-day average of $0.58 and 200-day average of $0.86 suggests the report could trigger outsized moves intraday on NASDAQ in USD trading.

Valuation and key LGVN stock financial metrics

Longeveron’s trailing price-to-sales is 14.05 and price-to-book is 1.74, while EV/Revenue stands near 8.30. The company shows limited leverage with debt-to-equity 0.10 and tangible book value per share $0.42. Gross margin is 74.88%, but operating margin is deeply negative at -15.43%, reflecting clinical-stage spend. These ratios paint a biotech profile: high upside if clinical data is positive and high downside if cash guidance weakens.

Meyka AI rates LGVN with a score out of 100 and LGVN stock forecast

Meyka AI rates LGVN with a score of 65.59 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, and analyst signals. The company rating outside our model reads C / Sell on 16 Mar 2026, reflecting mixed fundamentals.

Meyka AI’s forecast model projects a short-term monthly value of $0.36, compared with the current price $0.89, implying a modeled downside of -59.45%. Forecasts are model-based projections and not guarantees.

Analyst price targets and LGVN stock outlook

MarketBeat lists a current analyst price target of $6.50, highlighting the gap between some bullish analyst models and Meyka’s model projection. Realistic intraday price targets for traders might be conservative $0.50, base $1.50, and a bull scenario aligned with the MarketBeat target at $6.50 if clinical or partnership news appears. Given the sector dynamics in Biotechnology, LGVN stock remains sensitive to clinical readouts and financing headlines.

Final Thoughts

Key takeaways for LGVN stock ahead of the 17 Mar 2026 pre-market Q4 release: the market price $0.89 and heavy pre-market volume show investors are positioned for a data-driven move. Financials show negative EPS -0.98, tight free cash flow and significant R&D spending, so guidance or trial updates are decisive. Meyka AI’s forecast model projects $0.36, implying -59.45% from today’s price, while outside analysts list a $6.50 target, illustrating a wide range of outcomes. Traders should watch cash commentary, enrollment updates, and any partnership news. Use the Meyka AI-powered market analysis platform to track live signals and compare model-based forecasts against analyst targets and market reaction. Forecasts are model projections and not guarantees; manage position size and risk accordingly.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.